← Back to Search

Kinase Inhibitor

Sunitinib for Kidney Cancer

Phase 2
Waitlist Available
Led By Lionel D Lewis, MD
Research Sponsored by Dartmouth-Hitchcock Medical Center
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up every 12 weeks from randomization until progression, estimated time frame is 18 months
Awards & highlights

Study Summary

This trial is testing whether two different drugs that treat kidney cancer, sunitinib and temsirolimus, are more effective when given sequentially than when given separately.

Eligible Conditions
  • Kidney Cancer

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~every 12 weeks from randomization until progression, estimated time frame is 18 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and every 12 weeks from randomization until progression, estimated time frame is 18 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Progression Free Survival
Secondary outcome measures
Clinical Response Rate as Measured by Best Response Achieved
To Characterize the Toxicity Profile

Side effects data

From 2019 Phase 2 trial • 305 Patients • NCT01984242
46%
Proteinuria
41%
Fatigue
37%
Arthralgia
30%
Cough
30%
Nausea
28%
Diarrhoea
28%
Epistaxis
26%
Rash
26%
Hypertension
22%
Abdominal pain
22%
Blood creatinine increased
20%
Musculoskeletal pain
20%
Pain in extremity
20%
Constipation
20%
Dysphonia
17%
Oedema peripheral
17%
Pruritus
17%
Upper respiratory tract infection
17%
Back pain
17%
Hypothyroidism
17%
Dyspnoea
15%
Headache
13%
Stomatitis
13%
Vomiting
13%
Mucosal inflammation
13%
Oropharyngeal pain
13%
Pyrexia
11%
Abdominal distension
11%
Hyperglycaemia
11%
Hyponatraemia
11%
Productive cough
11%
Dry mouth
11%
Nasal congestion
11%
Dry skin
9%
Haematuria
9%
Dizziness
9%
Chest pain
9%
Sinusitis
9%
Hypophosphataemia
9%
Hyperkalaemia
9%
Muscle spasms
9%
Night sweats
9%
Decreased appetite
7%
Adrenal insufficiency
7%
Gingival bleeding
7%
Flank pain
7%
Myalgia
7%
Neck pain
7%
Dyspepsia
7%
Blood lactate dehydrogenase increased
7%
Dehydration
7%
Hypoalbuminaemia
7%
Insomnia
7%
Acute kidney injury
7%
Nocturia
7%
Dyspnoea exertional
7%
Rhinorrhoea
7%
Haemorrhoids
7%
Pneumonia
7%
Tumour pain
7%
Rash erythematous
7%
Ecchymosis
7%
Platelet count decreased
7%
Protein total increased
7%
Contusion
7%
Dry eye
4%
Thrombocytopenia
4%
Anaemia
4%
Hypomagnesaemia
4%
Depression
4%
Weight decreased
2%
Pancreatitis acute
2%
Appendicitis
2%
Asthenia
2%
Bronchitis
2%
Muscle haemorrhage
2%
Limb Operation
2%
Embolism
2%
Hypertensive crisis
2%
Oedema
2%
Sepsis
2%
Femur fracture
2%
Paraesthesia
2%
Cardiomyopathy
2%
Urinary tract infection
2%
Diverticulitis
2%
Atrial fibrillation
2%
Anxiety
100%
80%
60%
40%
20%
0%
Study treatment Arm
Atezolizumab (Crossover)
Atezolizumab and Bevacizumab
Atezolizumab
Sunitinib
Sunitinib (Crossover)

Trial Design

1Treatment groups
Experimental Treatment
Group I: Alternating Sunitinib and TemsirolimusExperimental Treatment2 Interventions
A cycle is defined as: Sunitinib 50mg by mouth daily for 4 weeks followed by a two week rest Temsirolimus 25mg IV weekly for 4 weeks followed by a two week rest
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Sunitinib
2014
Completed Phase 3
~4380
Temsirolimus
2008
Completed Phase 2
~1940

Find a Location

Who is running the clinical trial?

Dartmouth-Hitchcock Medical CenterLead Sponsor
524 Previous Clinical Trials
2,543,302 Total Patients Enrolled
Lionel D Lewis, MDPrincipal InvestigatorDartmouth-Hitchcock Medical Center
2 Previous Clinical Trials
6 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
Phase II Study of Alternating Sunitinib and Temsirolimus
Lionel.D.Lewis, MD 2010. "Phase II Study of Alternating Sunitinib and Temsirolimus". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT01517243.
~3 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top